Inhibitors of menin and DOT1L can induce varying degrees of differentiation in MLL-rearranged AML, and IDH1/2 inhibitors also induce differentiation and are highly effective in IDH1/2-mutant AML14–16. Here, KMT2A is linked to acute myeloid leukemia.